One Hormone, Three Molecules: The Science Story Behind Melanotan II
Science rarely moves in a straight line. A research program sets out to answer one question, and decades later its results turn up in places no one planned for. Few examples illustrate that better than a family of lab-made molecules that began with a hormone most people have never heard of.
That hormone is alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH. From it came three synthetic relatives. One became a treatment for a rare skin disorder. Another became a prescription drug for women. The third, Melanotan II, never became a medicine at all, and its story explains a great deal about how drug design works.
Where it started
In the 1980s, a group of chemists and biologists at the University of Arizona in Tucson began tinkering with alpha-MSH. The natural hormone is a chain of 13 amino acids, the building blocks of proteins. In the body it breaks down within minutes, which makes it hard to study.
The Arizona team, including chemist Victor Hruby and biologist Mac Hadley, swapped individual building blocks to make the hormone sturdier and stronger. Their early success was a straight-chain version with two substitutions, later called Melanotan I.
They then went further. By trimming the chain down to seven core units and bonding two of them together to close a ring, they produced a compact, highly potent molecule. Chemists call that shape cyclic. The result was Melanotan II, often abbreviated MT2.
Five receptors, one key
To see why MT2 matters, it helps to know where alpha-MSH delivers its messages. The body has five melanocortin receptors, numbered MC1R through MC5R. Think of them as five different locks spread through the body.
- MC1R sits mainly on melanocytes, the cells that make skin pigment
- MC2R is found in the adrenal glands and responds to a different hormone, ACTH
- MC3R and MC4R are concentrated in the brain, where they help regulate appetite, energy use and other behavior
- MC5R appears in several tissues, including glands that produce oils and secretions
A well-designed drug usually fits one lock. MT2 does not. It turns on MC1R, MC3R, MC4R and MC5R, a property scientists call non-selectivity.
Why selectivity is the central fact
That lack of focus is the single most important thing to understand about MT2. It explains nearly everything that followed.
When a molecule switches on receptors in the skin, the brain and elsewhere at the same time, it produces effects in all of those places at once. Researchers cannot keep the one they want and discard the rest. This was visible in the first small human study, reported by Robert Dorr and colleagues in 1996, which recorded nausea, flushing, yawning and spontaneous erections alongside changes in skin pigment (Dorr and colleagues, 1996).
For a drug developer, that combination is a problem. A medicine needs a clear purpose and a predictable profile, and MT2 offered neither. Development of MT2 itself stopped there.
The first descendant: afamelanotide
The straight-chain cousin, Melanotan I, took a different route. It leans much more heavily toward MC1R, the pigment-cell receptor, and that focus made a medical use possible.
Under its generic name, afamelanotide, it was developed as a treatment for erythropoietic protoporphyria, an inherited condition in which exposure to light causes severe pain. European regulators cleared it in 2014, sold as Scenesse, in the form of an implant for adults with the disorder (European Medicines Agency). The FDA followed in 2019.
The second descendant: bremelanotide
The brain effects seen with MT2 opened another path. Researchers noticed that its action on the MC4R receptor in the brain had effects of its own, and they set out to build a molecule around that signal.
The result was bremelanotide, first known as PT-141. Chemically it is a close relative of MT2, differing at one end of the molecule. In 2019 the FDA approved it under the brand name Vyleesi, a prescription injection for premenopausal women with a specific, diagnosed low-desire condition (FDA prescribing information).
Tellingly, that label lists nausea and flushing as common side effects and warns about temporary rises in blood pressure and darkening of the skin. Those are the same off-target effects seen in the MT2 family, now measured and managed inside a regulated product.
What the safety record shows
MT2 itself has no such label, because it never completed the trials that would produce one. What exists instead is a scattered set of published case reports, including new or changing moles, melanoma and serious muscle and kidney problems. Reports on individual patients show an association rather than proof of cause, yet they are the reason medicines regulators in the UK and other countries have publicly warned people against the unlicensed products sold online.
MT2 remains unapproved in every country.
A note on research material
Pharmacologists still use melanocortin compounds to map how these receptors work, and MT2’s broad activity makes it a useful reference point in that kind of lab work. Scientists sourcing an MT2 peptide for such studies look for testing on each individual batch, such as purity readings from a chromatography instrument and a mass spectrometry check that the molecule is the one named on the label.
None of that makes a research vial equivalent to Scenesse or Vyleesi. Those approved products contain different molecules, made under regulated conditions for defined patients.
The bigger lesson
The MT2 family tree is a useful case study for anyone curious about how medicines are made. The same starting hormone, reworked along a single line of research, produced one compound that became a rare-disease treatment, one that became a prescription drug, and one that became a regulatory headache.
The difference came down to focus. The molecules that reached patients were the ones whose effects could be pinned to a purpose and measured. Research suppliers such as NextGenPeps offer the unapproved member of the family only as laboratory material, which is the only role it has ever legitimately held.
Research use only
MT2 holds no drug approval anywhere and exists legitimately only as a compound for qualified laboratory research. It is not intended for use in people or animals, or for any cosmetic purpose, and this feature does not offer medical